Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Autografting

A therapeutic platelet transfusion strategy is safe and feasible in patients after autologous peripheral blood stem cell transplantation

Abstract

Prophylactic platelet transfusions are considered as standard in most hematology centers, but there is a long-standing controversy as to whether standard prophylactic platelet transfusions are necessary or whether this strategy could be replaced by a therapeutic transfusion strategy. In 106 consecutive cases of patients receiving 140 autologous peripheral blood stem cell transplantations, we used a therapeutic platelet transfusion protocol when patients were in a clinically stable condition. Platelet transfusions were only used when relevant bleeding occurred (more than petechial). Median duration of thrombocytopenia <20 × 109/l and <10 × 109/l was 6 and 3 days, which resulted in a total of 989 and 508 days, respectively. In only 26 out of 140 transplants (19%), we observed clinically relevant bleeding of minor or moderate severity. No severe or life-threatening bleeding was registered. The median and mean number of single donor platelet transfusions was one per transplant (range 0–18). One-third of all transplants, and 47% after high-dose melphalan could be performed without any platelet transfusion. Compared with a historical control group, we could reduce the number of platelet transfusions by one half. This therapeutic platelet transfusion strategy can be performed safely resulting in a considerable reduction in prophylactic platelet transfusions.

This is a preview of subscription content

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

References

  1. Gmür J, Burger J, Schanz U, Fehr J, Schaffner A . Safety of stringent prophylactic platelet transfusion policy for patients with acute leukemia. Lancet 1991; 338: 1223–1226.

    Article  PubMed  Google Scholar 

  2. Rebulla P, Finazzi G, Marangoni F, Avvisati G, Gugliotta L, Rognoni G et al. For the Gruppo Italiano Malattie Ematologiche Maligne Dell'Adulto. The threshold for prophylactic platelet transfusin in adults with acute myeloid leukemia. N Engl J Med 1997; 337: 1870–1875.

    CAS  Article  PubMed  Google Scholar 

  3. Heckman KD, Weiner GJ, Davis CS, Strauss RG, Jones MP, Burns P . Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukemia: 10 000/μl versus 20 000/μl. J Clin Oncol 1997; 15: 1143–1149.

    CAS  Article  PubMed  Google Scholar 

  4. Wandt H, Frank M, Ehninger G, Schneider C, Brack N, Daoud A et al. Safety and cost effectivenes of a 10 × 109/l trigger for prophylactic platelet transfusions compared with the traditional 20 × 109/l trigger: a prospective comparative trial in 105 patients with acute myeloid leukemia. Blood 1998; 91: 3601–3606.

    CAS  PubMed  Google Scholar 

  5. Gil-Fernández JJ, Alegre A, Fernández-Villalta MJ, Pinilla I, Gómez García V, Martinez C et al. Clinical results of a stringent policy on prophylactic platelet transfusion: non-randomized comparative analysis in 190 bone marrow transplant patients from a single institution. Bone Marrow Transplant 1996; 18: 931–935.

    PubMed  Google Scholar 

  6. Wandt H, Frank M, Gröschel W, Birkmann J, Gallmeier WM . Safety of the 10/nl trigger for prophylactic platelet transfusion in ASCT [abstract]. Bone Marrow Transplant 1995; 15 (Suppl 2): 541a.

    Google Scholar 

  7. Zumberg MS, del Rosario MLU, Nejame CF, Pollock BH, Garzarella L, Kao KJ et al. A prospective randomized trial of prophylactic platelet transfusion and bleeding incidence in hematopoietic stem cell transplant recipients: 10 000/μl versus 20 000/μl trigger. Biol Blood Marrow Transplant 2002; 8: 569–576.

    Article  PubMed  Google Scholar 

  8. Bernstein SH, Nademanee AP, Vose JM, Tricot G, Fay JW, Negrin RS et al. A multicenter study of platelet recovery and utilization in patients after myeloablative therapy and hematopoietic stem cell transplantation. Blood 1998; 91: 3509–3517.

    CAS  PubMed  Google Scholar 

  9. Nevo S, Swan V, Enger C, Wojno KJ, Bitton R, Shabooti M et al. Acute bleeding after bone marrow transplantation (BMT) – incidence and effect on survival. A quantitative analysis in 1402 patients. Blood 1998; 91: 1469–1477.

    CAS  PubMed  Google Scholar 

  10. Schiffer CA, Anderson KC, Bennett CL, Bernstein S, Elting LS, Goldsmith M et al. Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001; 19: 1519–1538.

    CAS  Article  PubMed  Google Scholar 

  11. Link H, Böhme A, Cornely OA, Hoffken K, Kellner O, Kern WV et al. Antimicrobial therapy of unexplained fever in neutropenic patients – Guidelines of the Infectious Disease Working Party (AGIO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2003; 82 (Suppl 2): 105–117.

    Article  Google Scholar 

  12. Bearman SI, Appelbaum FR, Buckner CD, Petersen FB, Fisher LD, Clift RA et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1998; 6: 1562–1568.

    Article  Google Scholar 

  13. Moreau Ph, Facon Th, Attal M, Hulin C, Michallett M, Maloisel F et al. Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myélome 9502 randomized trial. Blood 2002; 99: 731–735.

    CAS  Article  PubMed  Google Scholar 

  14. Pisciotto PT, Benson K, Hume H, Glassman AB, Oberman H, Popovsky M et al. Prophylactic versus therapeutic platelet transfusion practices in hematology and/or oncology patients. Transfusion 1995; 35: 498–502.

    CAS  Article  PubMed  Google Scholar 

  15. Patten E, Toy P . Prophylactic platelet transfusion policies [abstract]. Blood 1998; 72 (Suppl 1): 283a.

    Google Scholar 

  16. Murphy S, Litwin S, Herring LM, Koch P, Remischovsky J, Donaldson MH et al. Indications for platelet transfusion in children with acute leukemia. Am J Hematol 1982; 12: 347–356.

    CAS  Article  PubMed  Google Scholar 

  17. Higby DJ, Cohen E, Holland JF, Sinks L . The prophylactic treatment of thrombocytopenie leukemia patients with platelets: a double blind study. Transfusion 1974; 14: 440–446.

    CAS  Article  PubMed  Google Scholar 

  18. Solomon J, Bofenkamp T, Fahey JL, Chillar RK, Beutler E . Platelet prophylaxis in acute non-lymphoblastic leukemia [letter]. Lancet 1978; 1: 267.

    CAS  Article  PubMed  Google Scholar 

  19. Schiffer CA . Prophylactic platelet transfusion. Transfusion 1992; 32: 295–298.

    CAS  Article  PubMed  Google Scholar 

  20. Patten E . Controversies in transfusion medicine. Prophylactic platelet transfusion revisited after 25 years: con. Transfusion 1992; 32: 381–385.

    CAS  Article  PubMed  Google Scholar 

  21. Sagmeister M, Oec L, Gmür J . A restrictive platelet transfusion policy allowing long-term support of outpatients with severe aplastic anemia. Blood 1999; 93: 3124–3126.

    CAS  PubMed  Google Scholar 

  22. Wandt H, Ehninger G, Gallmeier WM . New strategies for prophylactic platelet transfusion in patients with hematologic diseases. Oncologist 2001; 6: 446–450.

    CAS  Article  PubMed  Google Scholar 

  23. Ballen K, Becker PS, Yeap BY, Matthews B, Henry DH, Ford PA . Autologous stem-cell transplantation can be performed safely without the use of blood-product support. J Clin Oncol 2004; 20: 4087–4094.

    Article  Google Scholar 

Download references

Acknowledgements

We thank Rex Nichols for preparing the manuscript and the staff of the bone marrow transplant unit at the Nuremberg hospital for the continuous support during the study.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to H Wandt.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Wandt, H., Schaefer-Eckart, K., Frank, M. et al. A therapeutic platelet transfusion strategy is safe and feasible in patients after autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 37, 387–392 (2006). https://doi.org/10.1038/sj.bmt.1705246

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705246

Keywords

  • platelet transfusion
  • autologous transplantation
  • bleeding complication

Further reading

Search

Quick links